Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators.

Radiother Oncol. 2019 Jun 8;140:84-89. doi: 10.1016/j.radonc.2019.05.018. [Epub ahead of print]

PMID:
31185328
2.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
3.

Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.

Courau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A, Blery M, Aparicio T, Allez M, Le Bourhis L.

J Immunother Cancer. 2019 Mar 14;7(1):74. doi: 10.1186/s40425-019-0553-9.

4.

Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study.

Zhou YY, Du XJ, Zhang CH, Aparicio T, Zaanan A, Afchain P, Chen LP, Hu SK, Zhang PC, Wu M, Zhang QW, Wang H.

EBioMedicine. 2019 Mar;41:276-285. doi: 10.1016/j.ebiom.2019.02.043. Epub 2019 Feb 26.

5.

Comparison of mobility indices for predicting early death in older patients with cancer: the PF-EC cohort study.

Pamoukdjian F, Aparicio T, Zebachi S, Zelek L, Paillaud E, Canoui-Poitrine F.

J Gerontol A Biol Sci Med Sci. 2019 Feb 4. doi: 10.1093/gerona/glz024. [Epub ahead of print]

PMID:
30715144
6.

Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study.

Pamoukdjian F, Aparicio T, Canoui-Poitrine F, Duchemann B, Lévy V, Wind P, Ganne N, Sebbane G, Zelek L, Paillaud E.

Clin Nutr. 2018 Dec 13. pii: S0261-5614(18)32579-2. doi: 10.1016/j.clnu.2018.12.011. [Epub ahead of print]

PMID:
30583963
7.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T, Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N, Bouché O, Faucheron JL, Forestier J, Lecaille C, Manfredi S, Tougeron D, Terrebonne E, Chehimi M, Villing AL, Sarda C, Legoux JL, Benamouzig R, Aparicio T.

Eur J Surg Oncol. 2019 Mar;45(3):331-335. doi: 10.1016/j.ejso.2018.11.012. Epub 2018 Nov 22.

PMID:
30501999
8.

Improved Thermotolerance of Genome-Reduced Pseudomonas putida EM42 Enables Effective Functioning of the PL /cI857 System.

Aparicio T, de Lorenzo V, Martínez-García E.

Biotechnol J. 2019 Jan;14(1):e1800483. doi: 10.1002/biot.201800483. Epub 2018 Nov 26.

PMID:
30417965
9.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.

Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O.

Gastric Cancer. 2019 May;22(3):577-586. doi: 10.1007/s10120-018-0885-z. Epub 2018 Oct 11.

PMID:
30311042
10.

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.

Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY.

PLoS One. 2018 Sep 18;13(9):e0204117. doi: 10.1371/journal.pone.0204117. eCollection 2018.

11.

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.

Paillaud E, Soubeyran P, Caillet P, Cudennec T, Brain E, Terret C, Etchepare F, Mourey L, Aparicio T, Pamoukdjian F, Audisio RA, Rostoft S, Hurria A, Bellera C, Mathoulin-Pélissier S; G-CODE collaborators.

Eur J Cancer. 2018 Nov;103:61-68. doi: 10.1016/j.ejca.2018.07.137. Epub 2018 Sep 11.

PMID:
30212804
12.

Nuclear ARP2/3 drives DNA break clustering for homology-directed repair.

Schrank BR, Aparicio T, Li Y, Chang W, Chait BT, Gundersen GG, Gottesman ME, Gautier J.

Nature. 2018 Jul;559(7712):61-66. doi: 10.1038/s41586-018-0237-5. Epub 2018 Jun 20.

13.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

PMID:
29921730
14.

[Prevalence and susceptibility pattern of bacteria isolated from infected chronic wounds in adult patients].

Silva V, Marcoleta A, Silva V, Flores D, Aparicio T, Aburto I, Latrach C, Febré N.

Rev Chilena Infectol. 2018 Apr;35(2):155-162. doi: 10.4067/s0716-10182018000200155. Spanish.

15.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.

Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J.

Br J Cancer. 2018 Aug;119(4):424-428. doi: 10.1038/s41416-018-0133-7. Epub 2018 Jun 6.

PMID:
29872148
16.

Reply to M. Mo et al.

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bennouna J.

J Clin Oncol. 2018 Aug 10;36(23):2452-2453. doi: 10.1200/JCO.2018.78.9669. Epub 2018 Jun 4. No abstract available.

PMID:
29863977
17.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators.

Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

18.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

Aparicio T, Bouché O, Francois E, Retornaz F, Barbier E, Taieb J, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Bedenne L, Paillaud E; for PRODIGE 20 investigators.

Eur J Cancer. 2018 Jul;97:16-24. doi: 10.1016/j.ejca.2018.03.030. Epub 2018 May 16.

PMID:
29777975
19.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators.

Ann Oncol. 2018 Nov 1;29(11):2270. doi: 10.1093/annonc/mdx808. No abstract available.

20.

Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.

Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD, Zelek L, Aparicio T.

Int J Colorectal Dis. 2018 Aug;33(8):1125-1130. doi: 10.1007/s00384-018-3053-3. Epub 2018 Apr 21.

PMID:
29680896
21.

Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.

Hammoudi N, Eveno C, Lambert J, Maillet M, Glehen O, Goere D, Lourenco N, Allez M, Aparicio T, Pocard M, Gornet JM; BIG-RENAPE working group.

Eur J Surg Oncol. 2018 Jun;44(6):799-804. doi: 10.1016/j.ejso.2018.03.006. Epub 2018 Mar 17.

PMID:
29650418
22.

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study.

Benamouzig R, Benallaoua M, Saurin JC, Boubaya M, Cellier C, Laugier R, Vincent M, Boustière C, Gincul R, Samaha E, Grandval P, Aparicio T, Airinei G, Bejou B, Bon C, Raynaud JJ, Levy V, Sautereau D.

Therap Adv Gastroenterol. 2018 Feb 16;11:1756283X18756260. doi: 10.1177/1756283X18756260. eCollection 2018.

23.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.

PMID:
29438522
24.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.

PMID:
29409778
25.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E.

Dig Liver Dis. 2018 Mar;50(3):305-307. doi: 10.1016/j.dld.2017.12.023. Epub 2017 Dec 30.

PMID:
29402752
26.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.

Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S.

Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.

27.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J; PRODIGE 9 Investigators.

J Clin Oncol. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.

PMID:
29346040
28.

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Locher C, Batumona B, Afchain P, Carrère N, Samalin E, Cellier C, Aparicio T, Becouarn Y, Bedenne L, Michel P, Parc Y, Pocard M, Chibaudel B, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD).

Dig Liver Dis. 2018 Jan;50(1):15-19. doi: 10.1016/j.dld.2017.09.123. Epub 2017 Oct 6. Review.

PMID:
29174568
29.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.

30.

A standardized workflow for surveying recombinases expands bacterial genome-editing capabilities.

Ricaurte DE, Martínez-García E, Nyerges Á, Pál C, de Lorenzo V, Aparicio T.

Microb Biotechnol. 2018 Jan;11(1):176-188. doi: 10.1111/1751-7915.12846. Epub 2017 Nov 2.

31.

CRISPR/Cas9-Based Counterselection Boosts Recombineering Efficiency in Pseudomonas putida.

Aparicio T, de Lorenzo V, Martínez-García E.

Biotechnol J. 2018 May;13(5):e1700161. doi: 10.1002/biot.201700161. Epub 2017 Dec 4. Review.

PMID:
29058367
32.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators.

Ann Oncol. 2018 Jan 1;29(1):133-138. doi: 10.1093/annonc/mdx529. Erratum in: Ann Oncol. 2018 Nov 1;29(11):2270.

33.

Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.

Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Réglat A, Pariente A, Aparicio T, Miremont-Salamé G, Noize P.

Target Oncol. 2017 Dec;12(6):805-814. doi: 10.1007/s11523-017-0529-y.

PMID:
29022151
34.

Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study.

Pamoukdjian F, Canoui-Poitrine F, Longelin-Lombard C, Aparicio T, Ganne N, Wind P, Martinez-Tapia C, Audureau E, Sebbane G, Zelek L, Paillaud E.

Oncotarget. 2017 Apr 21;8(31):50393-50402. doi: 10.18632/oncotarget.17361. eCollection 2017 Aug 1.

35.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.

36.

Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Lecomte P, Binquet C, Le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F, Lombard-Bohas C, Baudin E, Delemer B, Klein M, Vergès B, Aparicio T, Cosson E, Beckers A, Caron P, Chabre O, Chanson P, Du Boullay H, Guilhem I, Niccoli P, Rohmer V, Guigay J, Vulpoi C, Scoazec JY, Goudet P.

World J Surg. 2018 Jan;42(1):143-152. doi: 10.1007/s00268-017-4135-z.

PMID:
28785839
37.

Genomic Profiling of Small-Bowel Adenocarcinoma.

Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ.

JAMA Oncol. 2017 Nov 1;3(11):1546-1553. doi: 10.1001/jamaoncol.2017.1051.

38.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators.

Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11.

PMID:
28501762
39.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
40.

Impaired mobility, depressed mood, cognitive impairment and polypharmacy are independently associated with disability in older cancer outpatients: The prospective Physical Frailty in Elderly Cancer patients (PF-EC) cohort study.

Pamoukdjian F, Aparicio T, Zelek L, Boubaya M, Caillet P, François V, de Decker L, Lévy V, Sebbane G, Paillaud E.

J Geriatr Oncol. 2017 May;8(3):190-195. doi: 10.1016/j.jgo.2017.02.003. Epub 2017 Feb 22.

PMID:
28236586
41.

Preferences about information and decision-making among older patients with and without cancer.

Paillaud E, Canoui-Poitrine F, Varnier G, Anfasi-Ebadi N, Guery E, Saint-Jean O, Gisselbrecht M, Aparicio T, Bastuji-Garin S, Laurent M, Caillet P.

Age Ageing. 2017 Jul 1;46(4):665-671. doi: 10.1093/ageing/afw256.

PMID:
28104597
42.

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouché O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepère C, Khemissa F, Sobhani I, Boulat O, Mitry E, Jouve JL; FFCD 2001-02 investigators.

Eur J Cancer. 2017 Mar;74:98-108. doi: 10.1016/j.ejca.2016.09.029. Epub 2016 Nov 5.

PMID:
27825697
43.

Engineering Gram-Negative Microbial Cell Factories Using Transposon Vectors.

Martínez-García E, Aparicio T, de Lorenzo V, Nikel PI.

Methods Mol Biol. 2017;1498:273-293.

PMID:
27709582
44.

BRCA1-CtIP interaction in the repair of DNA double-strand breaks.

Aparicio T, Gautier J.

Mol Cell Oncol. 2016 Mar 30;3(4):e1169343. doi: 10.1080/23723556.2016.1169343. eCollection 2016 Jul.

45.

Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.

Mary F, Zaanan A, Boige V, Artru P, Samalin E, Coriat R, Bachet JB, Boubaya M, Benallaoua M, Tougeron D, Afchain P, Locher C, Baumgaertner I, Lecaille C, des Guetz G, Aparicio T; AGEO (Association des Gastro-Entérologues Oncologues).

Dig Liver Dis. 2016 Dec;48(12):1498-1502. doi: 10.1016/j.dld.2016.07.022. Epub 2016 Aug 9.

PMID:
27623185
46.

Small Bowel Adenocarcinoma.

Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR.

Gastroenterol Clin North Am. 2016 Sep;45(3):447-57. doi: 10.1016/j.gtc.2016.04.004. Review.

PMID:
27546842
47.

The Ssr protein (T1E_1405) from Pseudomonas putida DOT-T1E enables oligonucleotide-based recombineering in platform strain P. putida EM42.

Aparicio T, Jensen SI, Nielsen AT, de Lorenzo V, Martínez-García E.

Biotechnol J. 2016 Oct;11(10):1309-1319. doi: 10.1002/biot.201600317. Epub 2016 Jul 15.

PMID:
27367544
48.

Colorectal cancer care in elderly patients: Unsolved issues.

Aparicio T, Pamoukdjian F, Quero L, Manfredi S, Wind P, Paillaud E.

Dig Liver Dis. 2016 Oct;48(10):1112-8. doi: 10.1016/j.dld.2016.05.011. Epub 2016 May 19. Review.

PMID:
27260332
49.

MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts.

Aparicio T, Baer R, Gottesman M, Gautier J.

J Cell Biol. 2016 Feb 15;212(4):399-408. doi: 10.1083/jcb.201504005.

50.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A.

J Natl Cancer Inst. 2016 Feb 1;108(7). doi: 10.1093/jnci/djv438. Print 2016 Jul.

PMID:
26839356

Supplemental Content

Loading ...
Support Center